Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 12/2008

01-12-2008 | Review Article

Does Oxcarbazepine Warrant Therapeutic Drug Monitoring?

A Critical Review

Authors: Penny Bring, Dr Mary H. H. Ensom

Published in: Clinical Pharmacokinetics | Issue 12/2008

Login to get access

Abstract

Oxcarbazepine, the 10-keto analogue of carbamazepine, is approved for the treatment of partial seizures or generalized tonic-clonic seizures. The primary metabolite of oxcarbazepine is monohydroxylated derivative (MHD). This review follows a decision-making algorithm to determine if therapeutic drug monitoring of MHD is warranted.
Important factors to take into account include the appropriateness of oxcarbazepine for the therapeutic indication; ability to measure MHD concentrations; existence of a good concentration-response relationship, narrow therapeutic range or unpredictable pharmacokinetic parameters; assessability of the pharmacological response of oxcarbazepine; adequate duration of therapy; and potential influence of MHD concentrations in the clinical decision-making process. Based on the available evidence, therapeutic drug monitoring of MHD is not routinely warranted but may be beneficial in optimizing seizure control at the extremes of age, during pregnancy, in renal insufficiency, or to determine the significance of potential drug interactions or rule out noncompliance.
Literature
1.
Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the “common” neurologic disorders? Neurology 2007; 68: 326–37PubMedCrossRef
2.
3.
4.
5.
6.
Alves G, Figueiredo I, Castel-Branco M, et al. Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. Biomed Chromatogr 2007; 21: 1127–34PubMedCrossRef
7.
8.
Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001; 15: 137–63PubMedCrossRef
9.
Neels HM, Sierens AC, Naelaerts K, et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004; 42: 1228–55PubMedCrossRef
10.
Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006; 45: 1061–75PubMedCrossRef
11.
12.
Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Invest 2004; 24: 185–203CrossRef
13.
Garnett WR, Anderson GD, Collins RJ. Antiepileptic drugs. In: Burton ME, Shaw LM, Schentag JJ, et al., editors. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. Philadelphia (PA): Lippincott Williams & Wilkins, 2006: 502–5
14.
Breton H, Cociglio M, Bressolle F, et al. Liquid chromatrography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. J Chromatogr B 2005; 828: 80–90CrossRef
15.
Glauser TA, Pippenger CE. Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia 2000; 41 Suppl. 8: S6–S15PubMedCrossRef
16.
Flesch G, Tudor D, Souppart C, et al. Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects. Int J Clin Pharmacol Ther 2002; 40: 524–32PubMed
17.
Armijo JA, Vega-Gil N, Shushtarian M, et al. 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit 2005; 27: 199–204PubMedCrossRef
18.
Pucci V, Raggi MA. Analysis of antiepileptic drugs in biological fluids by means of electrokinetic chromatography. Electrophoresis 2005; 26: 767–82PubMedCrossRef
19.
Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006; 45: 351–63PubMedCrossRef
20.
Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24: 91–103PubMedCrossRef
21.
Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38: 191–204PubMedCrossRef
22.
Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet 2007; 46: 209–19PubMedCrossRef
23.
Splinter MY. Pharmacokinetic properties on new antiepileptic drugs. J Pharm Pract 2005; 18: 444–60CrossRef
24.
May TW, Rambeck B, Salke-Kellermann A. Flucutations of 10-hydroxy-carbazepine during the day in epileptic patients. Acta Neurol Scand 1996; 93: 393–7PubMedCrossRef
25.
Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs 2007; 21: 765–74PubMedCrossRef
26.
Ensom MHH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet 1998; 34: 265–79PubMedCrossRef
27.
French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology 2004; 62: 1252–60PubMedCrossRef
28.
French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Neurology 2004; 62: 1261–73PubMedCrossRef
29.
30.
Guay DRP. Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. Am J Geriatr Pharmacother 2003; 1: 18–37PubMedCrossRef
31.
Pratoomsri W, Yatham L, Bond DJ, et al. Oxcarbazepine in the treatment of bipolar disorder: a review. Can J Psychiatry 2006; 51: 540–5PubMed
32.
33.
Van Parys J, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsy Res 1994; 19: 79–85PubMedCrossRef
34.
Bill P, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195–204PubMedCrossRef
35.
Juenke JM, Brown PI, Urry FM, et al. Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV. J Chromatogr Sci 2006; 44: 45–8PubMed
36.
Greiner C, Haen E. Development of a simple column-switching high-performance liquid chromatography (HPLC) method for rapid and simultaneous routine serum monitoring of lamotrigine, oxcarbazepine, and 10-monohydroxycarbazepine (MHD). J Chromatogr B Analyt Technol Biomed Life Sci 2007; 854: 338–44PubMedCrossRef
37.
Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25: 347–63PubMedCrossRef
38.
Pienimaki P, Fuchs S, Isojarvi J, et al. Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high-performance liquid chromatography. J Chromatogr B 1995; 673: 97–105CrossRef
39.
Mazzucchelli I, Franco V, Fattore C, et al. A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in the human plasma. Ther Drug Monit 2007; 29: 319–24PubMedCrossRef
40.
Kimiskidis V, Spanakis M, Niopas I, et al. Development and validation of a high performance liquid chromatographic method for the determination of ox-carbazepine and its main metabolites in human plasma and cerebrospinal fluid and its application to pharmacokinetic study. J Pharm Biomed Anal 2007; 43: 763–8PubMedCrossRef
41.
Contin M, Balboni M, Callegati E, et al. Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. J Chromatogr B 2005; 828: 113–7CrossRef
42.
Franceschi L, Furlanut M. A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients. Pharmacol Res 2005; 51: 297–302PubMedCrossRef
43.
Mandrioli R, Ghedini N, Albani F, et al. Liquid chromatographic determination of oxcarbazepine and its metabolites in plasma of epileptic patients after solidphase extraction. J Chromatogr B 2003; 783: 253–63CrossRef
44.
Levert H, Odou P, Robert H. LC determination of oxcarbazepine and its active metabolite in human serum. J Pharm Biomed Anal 2002; 28: 517–25PubMedCrossRef
45.
Souppart C, Decherf M, Humbert H, et al. Development of a high throughput 96-well plate sample preparation method for the determination of trileptal (ox-carbazepine) and its metabolites in human plasma. J Chromatogr B 2001; 762: 9–15CrossRef
46.
Vermeij T, Edelbroek P. Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 857: 40–6PubMedCrossRef
47.
Bugamelli F, Sabbioni C, Mandrioli R, et al. Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatrography after solid-phase extraction. Anal Chim Acta 2002; 472: 1–10CrossRef
48.
Johannessen SI. Can pharmacokinetic variability be controlled for the patient’s benefit? The place of TDM for new AEDs. Ther Drug Monit 2005; 27: 710–3PubMedCrossRef
49.
Borusiak P, Korn-Merker E, Holert N, et al. Oxcarbazepine in treatment of childhood epilepsy: a survey of 46 children and adolescents. J Epilepsy 1998; 11: 355–60CrossRef
50.
51.
Gonzalez-Esquivel DF, Ortega-Gavilan M, Alcantara-Lopez G, et al. Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med Res 2000; 31: 202–5PubMedCrossRef
52.
Friis M, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224–7PubMedCrossRef
53.
Tomson T, Johannessen SI. Therapeutic drug monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 2000; 55: 697–705PubMedCrossRef
54.
Parant F, Bossu H, Gagnieu M, et al. Cross-reactivity assessment of carbamazepine-10,11-epoxide, oxcarbazepine, and 10-hydroxy-carbazepine in two automated carbamazepine immunoassays: PETINIA and EMIT 2000. Ther Drug Monit 2003; 25: 41–5PubMedCrossRef
55.
Nedelman JR, Gasparini M, Sallas W, et al. Oxcarbazepine: an analysis of concentration-efficacy/safety relationships. Neurology 1999; 52: A524–5
56.
Evans WE. General principles of clinical pharmacokinetics. In: Burton ME, Shaw LM, Schentag JJ, et al., editors. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2006: 3–29
57.
Striano S, Striano P, Di Nocera P, et al. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patient with epilepsy on high-dose oxcarbazepine therapy. Epilepsy Res 2006; 69: 170–6PubMedCrossRef
58.
Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000; 60: 23–33PubMedCrossRef
59.
May T, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21: 175–81PubMedCrossRef
60.
Tartara A, Galimberti C, Manni R, et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydrox-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 1993; 36: 366–8PubMedCrossRef
61.
Mckee P, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37: 27–32PubMedCrossRef
62.
Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of ox-carbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006; 47: 504–9PubMedCrossRef
63.
Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 2006; 67: 1497–9PubMedCrossRef
64.
Gareri P, Gravina T, Ferreri G, et al. Treatment of epilepsy in the elderly. Prog Neurobiol 1999; 58: 389–407PubMedCrossRef
65.
van Heiningen P, Eve M, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50: 410–9PubMedCrossRef
66.
Commission on Antiepileptic Drugs. Guidelines for therapeutic monitoring of antiepileptic drugs. Epilepsia 1993; 34: 585–7CrossRef
Metadata
Title
Does Oxcarbazepine Warrant Therapeutic Drug Monitoring?
A Critical Review
Authors
Penny Bring
Dr Mary H. H. Ensom
Publication date
01-12-2008
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 12/2008
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/0003088-200847120-00002

Other articles of this Issue 12/2008

Clinical Pharmacokinetics 12/2008 Go to the issue

Review Article

The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals

Original Research Article

Glycopeptide Bone Penetration in Patients with Septic Pseudoarthrosis of the Tibia

Original Research Article

A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human Subjects

Original Research Article

Population Pharmacokinetics of Mycophenolic Acid

Original Research Article

Pharmacokinetics of Sapropterin in Patients with Phenylketonuria

Acknowledgement

Acknowledgement